 |
市場調查報告書
商品編碼
2007987
病毒載體生產市場：按工作流程、類型、產品/服務、應用、疾病、最終用戶和地區分類Viral Vector Manufacturing Market, By Workflow, By Type, By Product & Services, By Application, By Disease Indication, By End User, By Geography |
||||||
病毒載體生產市場預計在2026年達到38.746億美元，預計2033年將達到88.291億美元。預計從2026年到2033年，其複合年成長率將達到17.6%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 38.746億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 17.60% | 2033年市場規模預測： | 88.291億美元 |
全球病毒載體生產市場是現代生物技術和製藥產業的關鍵組成部分，也是開發先進基因和細胞療法的基礎。病毒載體是經過基因改造的病毒，用於將治療基因遞送至目標細胞，是治療遺傳性疾病、癌症和多種其他疾病的重要工具。
這些先進生物製藥的生產需要專門的設施、先進的技術和嚴格的品管措施，以確保其安全性和有效性。隨著基因治療領域在突破性治療方法和監管核准的推動下經歷前所未有的成長，對高品質病毒載體生產服務的需求也急劇上升。該市場涵蓋多種類型的載體，包括慢病毒、逆轉錄病毒、腺病毒和腺結合病毒（AAV）載體，每種載體都需要獨特的生產過程和專業知識。合約研發生產機構（CDMO）在這一生態系統中扮演著至關重要的角色，為生物技術公司和大型製藥公司提供必要的服務。病毒載體生產的複雜性，加上巨額資金投入和監管合規要求，催生了一個快速發展、高度專業化的市場細分領域，而這一領域的發展動力源於技術的進步和治療應用的不斷拓展。
市場動態
全球病毒載體生產市場的主要驅動力是基因和細胞療法核准數量的指數級成長，以及全球監管機構對這些創新治療方法的日益認可。遺傳性疾病、癌症和罕見疾病的盛行率不斷上升，顯著增加了對個人化醫療解決方案的需求，使病毒載體成為治療性基因的重要遞送機制。製藥公司在研發方面的大量投入，以及生物技術Start-Ups創業投資投資，正在加速市場擴張。然而，該市場也面臨諸多限制因素，包括病毒載體生產成本極高、監管要求複雜且因地域而異，以及與規模化和產量最佳化相關的技術挑戰。
專業製造設施和熟練人員的匱乏進一步限制了市場成長，因為企業在滿足不斷成長的需求的同時，難以維持品質標準。供應鏈的複雜性和漫長的研發週期也構成了市場進入的重大障礙。
儘管如此，製造流程的技術進步帶來了巨大的機遇，例如懸浮細胞培養系統、一次性生物反應器和自動化生產平台的開發，這些技術有望降低成本並提高效率。針對不同治療領域的基因治療產品線不斷擴展，預示著廣闊的成長前景，而新興市場則蘊藏著巨大的市場擴張潛力。生物技術公司與成熟的合約研發生產機構（CDMO）之間的策略合作正在創造協同效應，從而實現早期市場准入並降低風險。此外，政府透過資助舉措和有利的法規結構加強支持力度，預計將進一步促進市場成長。
本次調查的主要特點。
- 本報告對全球病毒載體生產市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模和複合年成長率（%）。
- 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數介紹了全球病毒載體生產市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過分析全球病毒載體生產市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場範圍
- 報告摘要
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 法規環境
- 產品上市及核准
- PEST分析
- 波特的分析
- 市場機遇
- 法規環境
- 主要進展
- 產業趨勢
第4章 全球病毒載體生產市場：依工作流程分類，2021-2033年
- 下游製造
- 上游製造
第5章 全球病毒載體生產市場：依類型分類，2021-2033年
- 腺結合病毒（AAV）
- 慢病毒
- 逆轉錄病毒
- 腺病毒
- 其他
第6章 全球病毒載體生產市場：依產品與服務分類，2021-2033年
- 產品
- 服務
第7章 全球病毒載體生產市場：依應用領域分類，2021-2033年
- 細胞療法和基因療法
- 疫苗研發
- 研究
第8章 全球病毒載體生產市場：依疾病分類，2021-2033年
- 癌症
- 一般疾病
- 感染疾病
- 其他
第9章 全球病毒載體生產市場：依最終用戶分類，2021-2033年
- 製藥和生物製藥公司
- 學術機構和研究機構
- 其他
第10章 全球病毒載體生產市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第11章 競爭格局
- Lonza
- Catalent
- Thermo Fisher Scientific
- FUJIFILM Diosynth Biotechnologies
- Merck KGaA
- AGC Biologics
- Charles River Laboratories
- Oxford Biomedica
- Viralgen
- Minaris Advanced Therapies
- WuXi Advanced Therapies
- SK pharmteco
- Resilience
- uniQure
- Novartis Gene Therapies
第12章 分析師建議
- 機會
- 分析師意見
- Coherent Opportunity Map
第13章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
Viral Vector Manufacturing Market is estimated to be valued at USD 3,874.6 Mn in 2026 and is expected to reach USD 8,829.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 17.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,874.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 17.60% | 2033 Value Projection: | USD 8,829.1 Mn |
The global viral vector manufacturing market represents a critical component of the modern biotechnology and pharmaceutical landscape, serving as the backbone for advanced gene and cell therapy development. Viral vectors are genetically modified viruses engineered to deliver therapeutic genes into target cells, making them indispensable tools in treating genetic disorders, cancers, and various other diseases.
The manufacturing of these sophisticated biological products requires specialized facilities, advanced technologies, and stringent quality control measures to ensure safety and efficacy. As the gene therapy sector experiences unprecedented growth, driven by breakthrough treatments and regulatory approvals, the demand for high-quality viral vector manufacturing services has surged dramatically. The market encompasses various vector types including lentiviral, retroviral, adenoviral, and adeno-associated virus (AAV) vectors, each requiring distinct manufacturing processes and expertise. Contract development and manufacturing organizations (CDMOs) play a pivotal role in this ecosystem, providing essential services to biotechnology companies and pharmaceutical giants alike. The complexity of viral vector production, combined with significant capital requirements and regulatory compliance demands, has created a specialized market segment that continues to evolve rapidly with technological advancements and increasing therapeutic applications.
Market Dynamics
The global viral vector manufacturing market is primarily driven by the exponential growth in gene and cell therapy approvals, with regulatory agencies worldwide demonstrating increased acceptance of these innovative treatments. The rising prevalence of genetic disorders, cancer, and rare diseases has created substantial demand for personalized medicine solutions, positioning viral vectors as essential delivery mechanisms for therapeutic genes. Significant investments in research and development by pharmaceutical companies, coupled with venture capital funding for biotechnology startups, have accelerated market expansion. However, the market faces considerable restraints including the extremely high manufacturing costs associated with viral vector production, complex regulatory requirements that vary across different regions, and technical challenges related to scalability and yield optimization.
The shortage of specialized manufacturing facilities and skilled workforce further constrains market growth, as companies struggle to meet increasing demand while maintaining quality standards. Supply chain complexities and lengthy development timelines also pose significant barriers to market entry.
Nevertheless, substantial opportunities exist through technological advancements in manufacturing processes, including the development of suspension cell culture systems, single-use bioreactors, and automated production platforms that promise to reduce costs and improve efficiency. The expanding pipeline of gene therapies targeting various therapeutic areas presents lucrative growth prospects, while emerging markets offer untapped potential for market expansion. Strategic partnerships between biotechnology companies and established CDMOs are creating synergistic opportunities, enabling faster market access and risk mitigation. Additionally, increasing government support through funding initiatives and favorable regulatory frameworks is expected to further stimulate market growth.
Key Features of the Study
- This report provides in-depth analysis of the global viral vector manufacturing market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global viral vector manufacturing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Lonza, Catalent, Thermo Fisher Scientific, FUJIFILM Diosynth Biotechnologies, Merck KGaA, AGC Biologics, Charles River Laboratories, Oxford Biomedica, Viralgen, Minaris Advanced Therapies, WuXi Advanced Therapies, SK pharmteco, Resilience, uniQure, and Novartis Gene Therapies
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global viral vector manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector manufacturing market
Market Segmentation
- Workflow Insights (Revenue, USD Mn, 2021 - 2033)
- Downstream Manufacturing
- Purification
- Fill Finish
- Upstream Manufacturing
- Vector Amplification, Editing and Expansion
- Vector Recovery/Harvesting
- Type Insights (Revenue, USD Mn, 2021 - 2033)
- Adeno-associated viruses (AAVs)
- Lentiviruses
- Retroviruses
- Adenoviruses
- Others
- Product & Services Insights (Revenue, USD Mn, 2021 - 2033)
- Product
- Services
- Application Insights (Revenue, USD Mn, 2021 - 2033)
- Cell and Gene Therapy
- Vaccine Development
- Research
- Disease Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Cancer
- Generic Disorders
- Infectious Diseases
- Others
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Pharmaceutical and Biopharmaceutical Companies
- Academics and Research Institutes
- Others
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Lonza
- Catalent
- Thermo Fisher Scientific
- FUJIFILM Diosynth Biotechnologies
- Merck KGaA
- AGC Biologics
- Charles River Laboratories
- Oxford Biomedica
- Viralgen
- Minaris Advanced Therapies
- WuXi Advanced Therapies
- SK pharmteco
- Resilience
- uniQure
- Novartis Gene Therapies
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Viral Vector Manufacturing Market, By Workflow
- Global Viral Vector Manufacturing Market, By Type
- Global Viral Vector Manufacturing Market, By Product & Services
- Global Viral Vector Manufacturing Market, By Application
- Global Viral Vector Manufacturing Market, By Disease Indication
- Global Viral Vector Manufacturing Market, By End User
- Global Viral Vector Manufacturing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Viral Vector Manufacturing Market, By Workflow, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Downstream Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Purification
- Fill Finish
- Upstream Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Vector Amplification, Editing and Expansion
- Vector Recovery/Harvesting
5. Global Viral Vector Manufacturing Market, By Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adeno-associated viruses (AAVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Lentiviruses
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retroviruses
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Adenoviruses
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Viral Vector Manufacturing Market, By Product & Services, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Product
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Viral Vector Manufacturing Market, By Application, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cell and Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Vaccine Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Viral Vector Manufacturing Market, By Disease Indication, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Generic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. Global Viral Vector Manufacturing Market, By End User, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pharmaceutical and Biopharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Academics and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. Global Viral Vector Manufacturing Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Lonza
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Catalent
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Diosynth Biotechnologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AGC Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Charles River Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Oxford Biomedica
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viralgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Minaris Advanced Therapies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- WuXi Advanced Therapies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- SK pharmteco
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Resilience
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- uniQure
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis Gene Therapies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
